Ireland
--:--IST
Latest
Budget 2027: €29.1bn for Health, Rare Disease Medicines Pilot Ireland Needs 46,000 More Digital Specialists by 2030, EGFSN Report Warns Project Management Failures: Lessons for Healthcare FDA Approves Lilly's Weekly Insulin Onswik to Rival Awiqli WeBuild Programme: 50+ Women-Led Ventures and How to Apply Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Budget 2027: €29.1bn for Health, Rare Disease Medicines Pilot Ireland Needs 46,000 More Digital Specialists by 2030, EGFSN Report Warns Project Management Failures: Lessons for Healthcare FDA Approves Lilly's Weekly Insulin Onswik to Rival Awiqli WeBuild Programme: 50+ Women-Led Ventures and How to Apply Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity
Clinical Trials in France / NCT04185272
Recruiting Not applicable

Butyrophilins Role in Colon Cancer

NCT04185272 · tracked via the Priya Life Science France tracker
Sponsor
Institut Paoli-Calmettes
Phase
Not applicable
Started
2020-06-30
Last updated
2026-10-01

Condition(s) studied

Colonic Cancer

Investigational drug(s) / intervention(s)

analysis of BTN and BTNL status

analysis of BTN and BTNL status: analysis of BTN and BTNL expression in colon cancer and hepatic metastasis

Study summary

quantification of BTNL molecules in colon cancer in order to determinate if their could be used as a prognostic marquer

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient is older than 18 years old, * Signed participation consent, * Non-metastatic colon cancer immediately resectable or metastatic and liver synchronous for which it was decided a combined colic and liver surgery (metastatic patient at the outset) in multidisciplinary consultation meeting. * Performance Status (PS) 0 or 1 * affiliated to the social security or beneficiary Exclusion Criteria: * Rectal cancer, colon cancer recurrence * Emergency of colon cancer Surgery * History of inflammatory disease of the digestive tract (Crohn's disease or ulcerative colitis) * Patient who received neoadjuvant therapy other than chemotherapy * Patient treated with immune-suppressors or long-course corticosteroids \<12 months * Pregnant women or likely to be pregnant (without effective contraception) or breastfeeding, * Person in urgent situation, person under legal protection measure, or unable to express his / her consent, * Impossibility of submitting to the medical examination of the test for geographical, social or psychological reasons

Primary outcome measure(s)

  • evaluation of BTNL3, BTNL8 and BTNL9 expression by transcriptomics and immunohistochemistry — 8 years
    healthy and cancerous colon ad metastasis (if applicable) will be analysed by

Trial sites (1)

FacilityCityRegionStatus
Institut Paoli-Calmettes Marseille France Recruiting

More Institut Paoli-Calmettes trials in France

Institut Paoli Calmettes Chronic Lymphatic Leukemia Database Recruiting
Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients Recruiting
Feasibility Study of a Sports-Inspired Onco-Coaching Progranm for Young Adults i Cancer Remission Recruiting
COaching and Prehabilitation: Faisability Study in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome Active, not recruiting
Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation Recruiting

Other trials for the same condition

Abdominal Massage After Colon Surgery for Cancer Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04185272 on ClinicalTrials.gov ↗ ← All trials in France